| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BIOT.201400046 |
| P698 | PubMed publication ID | 25186301 |
| P50 | author | Dirk Grimm | Q67484042 |
| Kathleen Börner | Q98389411 | ||
| Ellen Wiedtke | Q115599734 | ||
| P2093 | author name string | Ann-Kristin Mueller | |
| Chronis Fatouros | |||
| Dominik Niopek | |||
| Stefanie Große | |||
| Elena Senís | |||
| P2860 | cites work | DNA DSB repair pathway choice: an orchestrated handover mechanism | Q26861805 |
| Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients | Q28303521 | ||
| One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering | Q29547524 | ||
| RNA-guided genetic silencing systems in bacteria and archaea | Q29614421 | ||
| CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
| Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system | Q29615782 | ||
| Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression | Q29615784 | ||
| Improving CRISPR-Cas nuclease specificity using truncated guide RNAs | Q29616043 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver | Q30434933 | ||
| Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. | Q30458169 | ||
| Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors | Q30975099 | ||
| In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses | Q33327474 | ||
| Oligomerized pool engineering (OPEN): an 'open-source' protocol for making customized zinc-finger arrays | Q33508083 | ||
| Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. | Q33849553 | ||
| ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool | Q33957629 | ||
| Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells | Q34093413 | ||
| High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy | Q34329364 | ||
| The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems | Q34337685 | ||
| Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways | Q34530552 | ||
| Production methods for gene transfer vectors based on adeno-associated virus serotypes | Q34987161 | ||
| From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy | Q35180997 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines | Q37327641 | ||
| Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. | Q37420333 | ||
| A guide to genome engineering with programmable nucleases | Q38201212 | ||
| Gene therapy for inherited retinal degenerations | Q38202230 | ||
| Current status of haemophilia gene therapy | Q38206852 | ||
| Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors | Q42235082 | ||
| Targeted gene disruption in somatic zebrafish cells using engineered TALENs | Q42862072 | ||
| Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy | Q44976981 | ||
| Novel tools for production and purification of recombinant adenoassociated virus vectors | Q45752072 | ||
| Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs | Q24299641 | ||
| Cas9 as a versatile tool for engineering biology | Q24564294 | ||
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| Efficient genome editing in zebrafish using a CRISPR-Cas system | Q24610828 | ||
| Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems | Q24633670 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| P433 | issue | 11 | |
| P921 | main subject | CRISPR | Q412563 |
| Cas9 | Q16965677 | ||
| P304 | page(s) | 1402-1412 | |
| P577 | publication date | 2014-10-06 | |
| P1433 | published in | Biotechnology Journal | Q15716480 |
| P1476 | title | CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox | |
| P478 | volume | 9 |
| Q60912963 | A Self-Deleting AAV-CRISPR System for Genome Editing |
| Q42542096 | A modular toolbox for gRNA-Cas9 genome engineering in plants based on the GoldenBraid standard |
| Q36483327 | A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9 |
| Q37731772 | A multifunctional AAV-CRISPR-Cas9 and its host response |
| Q57562597 | AAVvector-mediated in vivo reprogramming into pluripotency |
| Q34047590 | Adeno-Associated Virus-Mediated Delivery of CRISPR-Cas Systems for Genome Engineering in Mammalian Cells. |
| Q90088501 | An Overview of the CRISPR-Based Genomic- and Epigenome-Editing System: Function, Applications, and Challenges |
| Q44620413 | An in vivo transfection system for inducible gene expression and gene silencing in murine hepatocytes |
| Q57164105 | Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases |
| Q39306038 | Applications of CRISPR/Cas9 in retinal degenerative diseases |
| Q38858314 | Applications of the CRISPR/Cas9 system in murine cancer modeling |
| Q92654317 | Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications |
| Q58584175 | Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives |
| Q91633615 | Bioethical issues in genome editing by CRISPR-Cas9 technology |
| Q64102677 | Biofabrication of Autologous Human Hepatocytes for Transplantation: How Do We Get There? |
| Q38688945 | CRISPR Editing Technology in Biological and Biomedical Investigation. |
| Q38348602 | CRISPR genome engineering and viral gene delivery: a case of mutual attraction |
| Q38848400 | CRISPR-Cas9 technology: applications and human disease modelling |
| Q41872391 | CRISPR/CAS9-Mediated Genome Editing of miRNA-155 Inhibits Proinflammatory Cytokine Production by RAW264.7 Cells |
| Q47117286 | CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes |
| Q48854625 | CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing. |
| Q36196813 | CRISPR/Cas9-The ultimate weapon to battle infectious diseases? |
| Q47095305 | CRISPR/Cas9: A Potential Life-Saving Tool. What's next? |
| Q57805680 | Cas9 is a multiple-turnover enzyme |
| Q40480698 | Cell-Penetrating Peptide-Mediated Delivery of Cas9 Protein and Guide RNA for Genome Editing. |
| Q93081530 | Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins |
| Q42177324 | Computational and molecular tools for scalable rAAV-mediated genome editing. |
| Q91875104 | Computational design of anti-CRISPR proteins with improved inhibition potency |
| Q50091892 | Considerations for Cardiac CRISPR. |
| Q52423208 | Cutting short the path to murine liver cancer models. |
| Q35925498 | Death receptor-based enrichment of Cas9-expressing cells |
| Q45863203 | Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia |
| Q99724691 | Delivery Approaches for Therapeutic Genome Editing and Challenges |
| Q39197557 | Delivery technologies for genome editing |
| Q34481059 | Development of an intein-mediated split-Cas9 system for gene therapy |
| Q64999440 | Editing the Central Nervous System Through CRISPR/Cas9 Systems. |
| Q51561728 | Editorial: Biotechnology Journal - we are looking forward to a new decade. |
| Q47884801 | Editorial: Biotechnology Journal 10 year Anniversary - Thank you for your continued support |
| Q35476162 | Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi |
| Q52431143 | Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9 |
| Q40403124 | Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells |
| Q26785927 | Engineered Viruses as Genome Editing Devices |
| Q90637862 | Engineering Cellular Signal Sensors based on CRISPR-sgRNA Reconstruction Approaches |
| Q55228025 | Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. |
| Q38990551 | Gene Editing and Genetic Lung Disease. Basic Research Meets Therapeutic Application |
| Q39013159 | Gene and cell-based therapies for inherited retinal disorders: An update |
| Q38749884 | Gene editing technology as an approach to the treatment of liver diseases |
| Q36675277 | Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications |
| Q40602766 | Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome. |
| Q37505823 | HIV-1 Latency and Eradication: Past, Present and Future |
| Q40677862 | HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites |
| Q59355428 | Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation |
| Q93216998 | High rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot |
| Q38498286 | High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges |
| Q35591457 | Hitting the target without pulling the trigger |
| Q45873745 | Immunity to CRISPR Cas9 and Cas12a therapeutics |
| Q94600320 | Improvement of muscular atrophy by AAV-SaCas9-mediated myostatin gene editing in aged mice |
| Q26748886 | In Vivo Delivery Systems for Therapeutic Genome Editing |
| Q39163867 | In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges |
| Q57032336 | In vivo epigenome editing and transcriptional modulation using CRISPR technology |
| Q47553772 | In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease |
| Q34043628 | In vivo genome editing using Staphylococcus aureus Cas9 |
| Q47103130 | Individual Differences in Social Behavior and Cortical Vasopressin Receptor: Genetics, Epigenetics, and Evolution |
| Q37411994 | Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9 |
| Q40263108 | In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models |
| Q28085748 | Liver-targeted gene therapy: Approaches and challenges |
| Q38706503 | Local knockdown of Nav1.6 relieves pain behaviors induced by BmK I. |
| Q90549130 | Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing |
| Q61813605 | Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses |
| Q36386251 | Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic |
| Q28078150 | Patterns of CRISPR/Cas9 activity in plants, animals and microbes |
| Q35225949 | Personalized therapeutic strategies for patients with retinitis pigmentosa |
| Q38818422 | Plasmodium meets AAV-the (un)likely marriage of parasitology and virology, and how to make the match |
| Q36598414 | Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. |
| Q38618624 | Proteomics in the genome engineering era. |
| Q41964540 | Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease |
| Q57371723 | Stimuli responsive polymer-based strategies for polynucleotide delivery |
| Q61445684 | Streamlined procedure for gene knockouts using all-in-one adenoviral CRISPR-Cas9 |
| Q40221792 | Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9. |
| Q54253608 | Synapse maintenance and restoration in the retina by NGL2. |
| Q64968805 | Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR/Cas9 in Gene Editing. |
| Q47585560 | Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes |
| Q38367820 | Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity |
| Q90971001 | Systemic AAV vectors for widespread and targeted gene delivery in rodents |
| Q37577414 | TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus |
| Q54979175 | Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles. |
| Q64228945 | Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer |
| Q35654689 | The CRISPR/Cas9 genome editing methodology as a weapon against human viruses |
| Q37148023 | The CRISPR/Cas9 system for gene editing and its potential application in pain research |
| Q40045823 | Therapeutic Gene Editing Safety and Specificity. |
| Q38858433 | Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes |
Search more.